[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"parkinsons-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:parkinsons-disease":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,105,0,25,[9,42,67,88,120,144,170,193,216,238,270,298,322,345,368,397,430,461,479,502,522,548,568,591,612],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100560405","combined-genome-and-rna-sequencing-for-genetic-diagnosis-of-parkinsonism-100560405",false,"NCT06576713","Combined Genome and RNA Sequencing for Genetic Diagnosis of Parkinsonism","Identification of the Missing Genetic Causes of Parkinsonian Syndromes: a Combined Approach by Genome and RNA Sequencing","ParkOmic","Inclusion Criteria:\n\n* Extrapyramidal syndrome beginning before or at the age of 40 or associated with a family history:\n* Dopaminergic denervation proven by ioflupane brain scintigraphy (DaTscan®)\n* DNAs from both asymptomatic parents available in biobank\n* Subject affiliated to a social protection health insurance scheme or beneficiary or beneficiary\n* Subject able to understand the objectives and risks related to the research and to give dated and signed informed consent\n\nExclusion Criteria:\n\n* \\- Contraindication for performing a superficial skin biopsy provided for by the protocol\n* Molecular cause of parkinsonism previously identified\n* Absence of prior genetic exploration by high-throughput DNA sequencing\n* Patient with late-onset sporadic parkinsonian syndrome (\\> 40 years) without family history\n* Patient with Parkinson's syndrome associated with a specific diagnosis (genetic or non-genetic pathology: exposure to neuroleptics, toxic origin)\n* Impossibility of providing the subject with informed information\n* Subject under judicial protection\n* Subject under guardianship or curatorship","ALL","18 Years",{"count":21,"type":22},14,"ESTIMATED","INTERVENTIONAL",[25],"NA","Despite the increasing availability and advances in the analysis of high-throughput DNA sequencing, the majority of patients with early-onset or familial parkinsonism remain without a molecular diagnosis.\n\nStudying the genetic forms of parkinsonian syndromes presents numerous clinical, scientific and therapeutic interests. In clinical practice, identifying the genetic cause in a patient allow to provide genetic counseling and estimate the risk of recurrence in their relatives. Establishing correlations between the genotype and phenotype of patients with genetically determined parkinsonism, allow to better anticipate the evolution of the disease, or even to highlight biomarkers during the presymptomatic phases. Finally, the proteins encoded by the genes implicated in familial parkinsonism represent potential therapeutic targets likely to be modulated by neuroprotective pharmacological agents, even in sporadic Parkinson's disease.\n\nIn this work,investigators aimed at elucidating the missing genetic causes of parkinsonism through the application of combined RNA and whole genome sequencing.",[28],"Parkinson's Disease","RECRUITING","2026-08-20",{"date":32,"type":33},"2026-08-21","ACTUAL",{"date":35,"type":33},"2025-01-14",{"date":37,"type":22},"2027-01-01",{"name":39,"class":40},"University Hospital, Strasbourg, France","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":41},"100218336","deep-brain-stimulation-therapy-in-movement-disorders-100218336","NCT02119611","Deep Brain Stimulation Therapy in Movement Disorders","* INCLUSION CRITERIA:\n\nTo be eligible for entry into the study, candidates must meet all the following criteria:\n\n* Be 18 years of age or older.\n* Able to comply with study procedures and provide informed consent.\n* Have a clinical diagnosis of idiopathic PD, primary dystonia, or ET:\n\n  1. The diagnosis of idiopathic PD will be based on the UK Brain Bank Criteria, and confirmed by the Movement Disorders Neurologists in the NIH Parkinson Clinic.\n  2. The diagnosis of primary (generalized or segmental), hemidystonia, or cervical dystonia will be confirmed on clinical examination in the NIH Movement Disorders Clinic.\n  3. The diagnosis of ET will be confirmed on clinical examination in the NIH Movement Disorders Clinic (the diagnosis of ET will be based on bilateral, largely symmetric postural or kinetic tremor involving hands and forearms that is visible and persistent. Additional or isolated tremor in head may be present but there should be the absence of abnormal posturing).\n* a. History of appropriate response to dopaminergic medication, with at least a 30% improvement in motor UPDRS with L-DOPA by history or in-clinic testing, for the PD patients. OR\n\n  b.Patients with tremor-dominant PD that do not respond to dopaminergic therapy and that exhibit a tremor score of at least 2 for tremor severity on at least one side of the body on the motor UPDRS examination.\n* Unsatisfactory clinical response to maximal medical management (with trials of both higher and lower doses of drugs), including:\n\nFor PD patients:\n\n1. good benefit from dopaminergic medication but associated with insufficient duration of action or unacceptable side-effects OR\n2. intractable disabling motor fluctuations (severe off periods, dyskinesias, or freezing spells) OR\n\n   For ET and dystonia:\n3. intractable symptoms of ET or dystonia impacting at least 2 activities of daily living.\n\n   * Interested in being evaluated to undergo DBS, if indicated, to treat medically refractory movement disorder or\n   * Patients already implanted with DBS for continued management\n\n(Note: Inclusion criteria 4 and 5 can be met by historical report in patients who had DBS implanted outside the NIH)\n\nEXCLUSION CRITERIA:\n\nFor those who have not had DBS:\n\nCandidates will be excluded if they meet any of the following criteria:\n\n* Clinically significant medical disease that would increase the risk of developing pre- or postoperative complications, including but not limited to uncontrolled systemic hypertension with values above 170\u002F100; unstable heart disease; unstable respiratory disease; uncorrected coagulation abnormalities or need for therapeutic anticoagulation which cannot be interrupted;\n* Evidence of secondary or atypical parkinsonism\u002Fdystonia\u002Ftremor as suggested by:\n\n  1. History of stroke, exposure to toxins, neuroleptics, or encephalitis\n  2. Neurologic signs of upper motor neuron or cerebellar involvement, supranuclear gaze palsy, or multiple systems atrophy.\n  3. MR-imaging with evidence indicative of secondary disease such as tumor, or stroke, which could cause the movement disorder.\n* Dementia as evidenced by formal neuropsychological evaluation, Mattis Dementia Rating Scale (DRS-2) score, and clinical evaluations.\n* Unable to complete cognitive assessments and testing necessary to adequately evaluate risks and benefits of surgery.\n* Clinically signficiant or unstable psychiatric disorder such as severe depression or anxiety, which, in the opinion of the investigators would increase the risk of developing postoperative complications.\n* Unable to undergo MR-imaging because of implanted pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent eye liner or small metal fragments in the eye that welders and other metal workers may have, or if candidates are uncomfortable in small closed spaces (have claustrophobia), or cannot lie comfortably on their back for up to one hour.\n* Pregnant women.\n* Otherwise not eligible for DBS surgery, for example known inability to undergo anesthesia\n\nFor those who have had DBS:\n\n-Contra-indications for ongoing stimulation, such as intractable side effects of DBS despite stimulation parameter adjustment","100 Years",{"count":50,"type":22},300,[25],"Background:\n\n\\- In deep brain stimulation (DBS), a device called a neurostimulator is placed in the chest. It is attached to wires in parts of the brain that affect movement. DBS might help people with movement disorders like Parkinson s disease (PD), dystonia, and essential tremor (ET).\n\nObjective:\n\n\\- To provide DBS treatment to people with some movement disorders.\n\nEligibility:\n\n\\- Adults 18 years and older with PD, ET, or certain forms of dystonia.\n\nDesign:\n\n* Participants will be screened with medical history and physical exam. They will have blood and urine tests and:\n* MRI brain scan. The participant will lie on a table that slides in and out of a metal cylinder with a magnetic field. They will be in the scanner about 60 minutes. They will get earplugs for the loud noises. During part of the MRI, a needle will guide a thin plastic tube into an arm vein and a dye will be injected.\n* Electrocardiogram. Metal disks or sticky pads will be placed on the chest, arms, and legs. They record heart activity.\n* Chest X-ray.\n* Tests of memory, attention, concentration, thinking, and movement.\n* Eligible participants will have DBS surgery. The surgery and hospital care afterward are NOT part of this protocol.\n* Study doctors will see participants 3 4 weeks after surgery to turn on the neurostimulator.\n* Participants will return every month for 3 months, then every 3 months during the first year, and every 6 months during the second year. Each time, participants will be examined and answer questions. DBS placement will be evaluated with MRI. The neurostimulator will be programmed. At two visits, participants will have tests of movements, thinking, and memory.",[28],[55,56,28,57,58],"Deep Brain Stimulation","Movement Disorders","Essential Tremor","Tourette Syndrome",{"date":32,"type":33},{"date":61,"type":33},"2014-04-02",{"date":63,"type":22},"2030-12-01",{"name":65,"class":66},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":23,"phases":75,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":41},"100652575","phase-1-an-unblinded-single-arm-pilot-observational-study-to-test-the-safety-tolerability-immunogenicity-and-the-biological-effects-of-trb-001-vaccination-in-individuals-who-have-previously-undergone-asyn-immunotherapy-100652575","NCT07777484","An Unblinded, Single Arm, Pilot Observational Study to Test the Safety, Tolerability, Immunogenicity and the Biological Effects of TRB-001 Vaccination in Individuals Who Have Previously Undergone aSyn Immunotherapy","Inclusion Criteria:\n\n* At least 18-years of age\n* Female or male with previous treatment with active aSyn immunotherapy\n* Parkinson's disease diagnosis (any stage)\n* Understands and agrees to comply with the study procedures and provides written informed consent\n\nExclusion Criteria:\n\n* Women of childbearing potential without use of contraception\n* Women who are pregnant or lactating\n* Contraindication for MRI or lumbar puncture\n* Known or suspected allergy, or history of anaphylaxis, to vaccines or their excipients, if considered relevant by the investigator\n* Presence or history of autoimmune disease or immunodeficiency, if considered relevant by the investigator\n* Presence of active infectious disease (hepatitis B, hepatitis C, or human immunodeficiency virus (HIV))\n* Significant cognitive impairment or clinical dementia, or a Montreal Cognitive Assessment (MoCA) score \\\u003C26\n* High suspicion of other parkinsonian syndromes, such as multiple system atrophy, progressive supranuclear palsy, drug-induced Parkinsonism and post-encephalitic Parkinsonism\n* Any relevant systemic illness. This includes cardiovascular, hepatic, gastroenterological, respiratory, endocrinological, hematologic disease, or any other condition that, in the investigator's opinion, could interfere with the analyses of safety and efficacy in this study, unless patient has been on stable doses of medication for any of these concurrent illnesses for at least 3 months prior to study entry\n* Unstable psychiatric illness, including psychosis, suicidal ideation, untreated major depression, schizophrenia, or bipolar affective disorder within 90 days before Visit 1, as determined by the investigator\n* History of drug or alcohol abuse within the past 5 years\n* Recent history (≤2 years) of cancer (exceptions; basal cell carcinoma, intraepithelial cervical neoplasia)\n* Birthmarks, tattoos, wounds, or skin conditions that may obscure the assessment of injection site reactions\n* Participation in the active treatment phase of any non-PD clinical trial within 30 days prior to Visit 1\n* Dose limiting toxicity to previous immunization with aSyn-based PD vaccine\n* Current immunosuppressive therapy\n* Employee at the study site, spouse\u002Fpartner or relative of any study staff (e.g. investigator, sub-investigators, or study nurse) or relationship to sponsor",{"count":74,"type":22},6,[76],"PHASE1","An unblinded, single arm, pilot observational study to test the safety, tolerability, immunogenicity and the biological effects of TRB-001 vaccination in individuals who have previously undergone aSyn immunotherapy",[28],"2026-08-17",{"date":30,"type":33},{"date":82,"type":33},"2026-07-28",{"date":84,"type":22},"2027-07",{"name":86,"class":87},"Tridem Bioscience FlexCo","INDUSTRY",{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":95,"sex":18,"minAge":19,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":99,"briefSummary":100,"conditions":101,"keywords":106,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":41},"100392965","phase-1-pet-imaging-of-cyclooxygenases-in-neurodegenerative-brain-disease-100392965","NCT04396873","PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease","Phase 1 Study: PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease","* INCLUSION CRITERIA:\n\nPatients: In order to be eligible to participate in this study, patients must meet all of the following criteria:\n\n1. Aged 18 or older.\n2. Be able (or have their Legally Authorized Representative (LAR) be able) to understand the study and be willing to sign a written informed consent document.\n3. Have been diagnosed by a neurologist or psychiatrist with MCI, ALS, PD, or an adult onset neurodegenerative dementia, such as AD (including amyloid negative subjects), FTD, corticobasal syndrome, or Huntington s disease.\n4. Be in good general health as evidenced by medical history and physical examination.\n5. Have their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n6. Agree to adhere to the lifestyle considerations.\n\nHealthy volunteers: In order to be eligible to participate in this study, healthy volunteer subjects must meet all of the following criteria:\n\n1. Aged 18 or older.\n2. Female participants of childbearing potential must be using a medically acceptable means of contraception\n3. Able provide informed consent.\n4. Be in good general health, as evidenced by medical history and physical examination, and have no cognitive impairment.\n5. Be enrolled in 01-M-0254, The Evaluation of Participants with Mood and Anxiety Disorders and Healthy Volunteers or 17-M-0181, Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies\n6. Have their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n7. Agree to adhere to the lifestyle considerations.\n\nEXCLUSION CRITERIA:\n\nBoth patients and healthy volunteers who meet any of the following criteria will be excluded from participation in this study:\n\n1. Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen). Any lab value that is two-times the upper limit or even lower values in the investigator s judgment. Creatinine level \\>1.3 mg\u002FdL\n2. Subjects should not have taken Non-Steroidal Anti-Inflammatory Drugs (NSAID) for two weeks prior to the PET scan. Aspirin, corticosteroids (with the exception of skin products), or immunosuppressants (e.g., methotrexate) must not have been taken in the prior month.\n3. Contraindications to ketoprofen, such as hypersensitivity to ketoprofen or history of upper or lower gastrointestinal bleeding.\n4. Have other major neurological or medical diseases that may cause cognitive dysfunction, such as structural brain diseases, metabolic diseases, paraneoplastic syndromes, infectious diseases, or other significant neurological abnormalities.\n5. Have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy).\n6. Are unable to travel to the NIH.\n7. Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits.\n8. Have an inability to lie flat and\u002For lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the patient and\u002For caregiver during the screening visit.\n9. Participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs function of daily life.\n10. Participants should not be under treatment with Aduhelm, nor should they have been treated in the past.\n11. Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye).\n12. Pregnancy\n13. HIV infection\n14. Be NIMH staff or an NIH employee who is a subordinate\u002Frelative\u002Fco-worker of the investigators.",true,"99 Years",{"count":98,"type":22},184,[76],"Background:\n\nAbout 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases. Researchers want to find a better way to measure this inflammation.\n\nObjective:\n\nTo learn whether COX-1 and\u002For COX-2 is elevated in the brains of individuals with neurodegenerative brain disease compared to healthy volunteers.\n\nEligibility:\n\nAdults age 18 years and older in good general health who have an adult-onset neurodegenerative dementia, such as AD, FTD, corticobasal syndrome, Huntington s disease, or MCI, ALS and healthy adult volunteers enrolled in protocols 01-M-0254 or 17-M-0181.\n\nDesign:\n\nParticipants will be screened with medical history, physical exam with vital signs, and lab tests. They will have a neuropsychological testing. Their heart function will be measured.\n\nParticipants will have a magnetic resonance imaging (MRI) scan. The MRI scanner is a metal tube surrounded by a strong magnetic field. Participants will lie on a table that slides in and out of the tube. The machine makes noise. Participants will get earplugs.\n\nParticipants will have 2 PET scans. They will be injected with the study drugs through an intravenous catheter placed in an arm vein. The PET scanner is shaped like a doughnut. Participants will lie on a bed that slides in and out of the scanner. A plastic mask will be molded to their head to keep them from moving. A thin plastic tube will be put into an artery at the wrist or elbow crease area. This will be used to draw blood during the scan.\n\nParticipants will have 2-5 study visits. Participation lasts 1 week to 4 months, depending on scheduling.",[28,102,103,104,105],"Dementia","Alzheimer's Disease","ALS","Mild Cognitive Impairment",[107,108,109,102,110,104,111],"PET Imaging","PD","Inflammation","Cyclooxygenase-2","MCI","2026-08-14",{"date":79,"type":33},{"date":115,"type":33},"2021-08-17",{"date":117,"type":22},"2030-10-03",{"name":119,"class":66},"National Institute of Mental Health (NIMH)",{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":96,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":41},"100177251","deep-brain-stimulation-surgery-for-movement-disorders-100177251","NCT01581580","Deep Brain Stimulation Surgery for Movement Disorders","* INCLUSION CRITERIA:\n\nTo be eligible for entry into the study, candidates must meet all the following criteria:\n\nBe 18 years of age or older.\n\nAble to provide informed consent.\n\nHave a clinical diagnosis of one of the following as confirmed by the NIH movement disorders clinic team and the multi-disciplinary DBS surgical conference, and deemed as appropriate for the use of Deep Brain Stimulation therapy:\n\n* idiopathic PD not adequately controlled with medication or\n* primary dystonia that is medically refractory, or\n* ET that is not adequately controlled by medications or constitutes a significant functional disability.\n\nEXCLUSION CRITERIA:\n\nCandidates will be excluded if they:\n\nAre unable or unwilling to give informed consent to the research procedures.",{"count":127,"type":22},200,[25],"Background:\n\n\\- Deep brain stimulation (DBS) is an approved surgery for certain movement disorders, like Parkinson's disease, that do not respond well to other treatments. DBS uses a battery-powered device called a neurostimulator (like a pacemaker) that is placed under the skin in the chest. It is used to stimulate the areas of the brain that affect movement. Stimulating these areas helps to block the nerve signals that cause abnormal movements. Researchers also want to record the brain function of people with movement disorders during the surgery.\n\nObjectives:\n\n* To study how DBS surgery affects Parkinson s disease, dystonia, and tremor.\n* To obtain information on brain and nerve cell function during DBS surgery.\n\nEligibility:\n\n\\- People at least 18 years of age who have movement disorders, like Parkinson's disease, essential tremor, and dystonia.\n\nDesign:\n\n* Researchers will screen patients with physical and neurological exams to decide whether they can have the surgery. Patients will also have a medical history, blood tests, imaging studies, and other tests. Before the surgery, participants will practice movement and memory tests.\n* During surgery, the stimulator will be placed to provide the right amount of stimulation for the brain. Patients will perform the movement and memory tests that they practiced earlier.\n* After surgery, participants will recover in the hospital. They will have a followup visit within 4 weeks to turn on and adjust the stimulator. The stimulator has to be programmed and adjusted over weeks to months to find the best settings.\n* Participants will return for followup visits at 1, 2, and 3 months after surgery. Researchers will test their movement, memory, and general quality of life. Each visit will last about 2 hours.",[28,57,131],"Dystonia",[28,55,133,134,131,135,57],"Neurophysiology","Movement Disorder","Parkinson Disease","2026-08-12",{"date":138,"type":33},"2026-08-13",{"date":140,"type":33},"2011-08-17",{"date":142,"type":22},"2029-12-01",{"name":65,"class":66},{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":150,"targetDuration":152,"studyType":153,"phases":4,"briefSummary":154,"conditions":155,"keywords":156,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":169},"100214628","registry-of-deep-brain-stimulation-with-the-vercise-system-vercise-dbs-registry-100214628","NCT02071134","Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry","Key Inclusion Criteria:\n\n* Meets criteria established in locally applicable Vercise System Direction for Use\n* At least 18 years old\n\nKey Exclusion Criteria:\n\n* Meets any contraindication in the Vercise System locally applicable Directions for Use\n\nSubjects with significant cognitive or psychiatric impairment may be excluded in the evaluation of GXT.",{"count":151,"type":22},1500,"3 Years","OBSERVATIONAL","The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease.\n\nThe utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated.\n\nAdditionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.",[28],[157,158,159],"Deep brain stimulation","Parkinson's disease","Vercise","2026-08-10",{"date":162,"type":33},"2026-08-11",{"date":164,"type":33},"2014-03-04",{"date":166,"type":22},"2038-12",{"name":168,"class":87},"Boston Scientific Corporation",85,{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":95,"sex":18,"minAge":177,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":41},"100594483","evaluation-of-tau-pathology-in-sporadic-and-lrrk2-parkinsons-disease-100594483","NCT07020026","Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease","Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease Using [18F]PI-2620: A High-resolution PET Imaging Study Using NeuroEXPLORER (NX PI-2160 in PD)","Inclusion Criteria:\n\nGeneral inclusion criteria include the following:\n\n1. Ability to comply with the study procedures and attend follow-up visits.\n2. Written informed consent from the participant or legal guardian.\n3. Male or Female between 45 years and 85 years of age (Females must meet additional criteria specified below, as applicable) a. Females must be of non-childbearing potential or using a highly effective method of birth control 14 days prior to until at least 24 hours after injection of \\[18F\\]PI-2620 or DaTscan.\n\ni. Non-childbearing potential is defined as a female that must be either postmenopausal (no menses for at least 12 months prior to PET scan) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy).\n\nii. Highly effective method of birth control is defined as practicing at least one of the following: A birth control method that results in a less than 1% per year failure rate when used consistently and correctly, such as oral contraceptives for at least 3 months prior to injection, an intrauterine device (IUD) for at least 2 months prior to injection, or barrier methods, e.g., diaphragm or combination condom and spermicide. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) is not acceptable.\n\nb. Females of childbearing potential must not be pregnant, breastfeeding or lactating, or planning pregnancy during the duration of the study.\n\nc. Non PPMI participant females of childbearing potential must have a negative serum pregnancy test at Screening and all females of childbearing potential must have negative urine pregnancy test prior to \\[18F\\]PI-2620 injection on day of Baseline PET scan.\n\nd. Non PPMI participant females of childbearing potential must have a negative urine pregnancy test prior to Screening Visit DaTscan injection.\n\nHealthy Controls:\n\na) Enrolled in the PPMI study as a healthy subject.\n\nDisease specific inclusion criteria:\n\na) Parkinson's disease\n\na. Enrolled in the PPMI study as a sporadic PD or LRRK2 PD participant. b. Known CSF alpha synuclein seeding amplification assay status. c. Known Plasma phosphorylated Tau217 status. b) Progressive Supranuclear Palsy (PSP):\n\n1. Diagnosis of progressive supranuclear palsy (PSP) based on the Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria (Höglinger et al., 2017).\n2. Symptom onset within 2-5 years prior to screening.\n3. Progressive motor symptoms including vertical supranuclear gaze palsy, postural instability, and other signs of parkinsonism.\n4. Evidence of striatal degeneration in form of abnormal DaTscan (previously obtained DaTscan since onset of motor symptoms may be used).\n\nc) Corticobasal Syndrome (CBS):\n\n1. Diagnosis of corticobasal syndrome (CBS) based on clinical criteria, with asymmetric motor and cognitive dysfunction (Armstrong et al., 2013).\n2. Presence of limb apraxia, dystonia, alien limb phenomenon, and\u002For parkinsonism (e.g., rigidity, bradykinesia).\n3. Cognitive decline as indicated by impairment in attention, executive function, or memory.\n4. Evidence of striatal degeneration in form of abnormal DaTscan (previously obtained DaTscan since onset of motor symptoms may be used).\n\nExclusion Criteria:\n\n1. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.\n2. For those receiving Screening DaTscan:\n\n   • Received any of the following medications that could interfere with the imaging and unwilling or medically unable to hold them for five half-lives before SPECT imaging: alpha methyldopa, methylphenidate, amphetamine derivatives or modafinil, bupropion, phentermine, phencyclidine, fentanyl, or medication commonly considered to interfere with Ioflupane binding per standard clinical practice.\n3. Received any of the following drugs: dopamine receptor blockers (neuroleptics), metoclopramide and reserpine, within 6 months of Screening Visit for non-PPMI participants or within 6 months of Baseline Visit for PPMI participants.\n4. Any structural abnormality or finding on previously obtained or screening brain MRI suggestive of clinically significant neurological disorders other than the diseases of interest (in the opinion of the investigator).\n5. Any other reason that in the opinion of the investigator, including abnormal labs, that could interfere with the safety with radiotracer injection, would render the participant unsuitable for the study enrollment.","45 Years","85 Years",{"count":180,"type":22},60,[182],"PHASE2","The study aims to evaluate the burden of tau pathology in people with Sporadic and LRRK2 PD via in vivo imaging using the tau tracer, \\[18F\\]PI-2620, and a high resolution PET camera, NeuroEXPLORER.",[28],"2026-08-06",{"date":160,"type":33},{"date":188,"type":33},"2025-05-12",{"date":190,"type":22},"2027-06",{"name":192,"class":40},"Michael J. Fox Foundation for Parkinson's Research",{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":12,"sex":18,"minAge":201,"maxAge":178,"enrollmentInfo":202,"targetDuration":4,"studyType":23,"phases":204,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":98},"100606342","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-iv-prasinezumab-in-participants-with-early-stage-parkinsons-disease-100606342","NCT07174310","A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease","A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease","PARAISO","Inclusion Criteria:\n\n* Body weight within 40-110 kilograms (kg) (88-242 pounds \\[lbs\\]) and a body mass index within the range 18-34 kg\u002Fm2\n* Diagnosis of idiopathic PD based on Movement Disorder Society (MDS) criteria\n* Has received monotherapy treatment\n* An MDS-UPDRS Part IV score of 0 at screening and prior to randomization\n* Hoehn and Yahr (H\\&Y) Stage 1 or 2 off medication at screening and prior to randomization\n* Agreement to adhere to the contraception requirements\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which contraception is required\n* Medical history indicating a parkinsonian syndrome other than idiopathic PD\n* Diagnosis of a significant neurologic disease other than PD\n* Chronic uncontrolled hypertension","50 Years",{"count":203,"type":22},900,[205],"PHASE3","The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.",[28],"2026-08-04",{"date":185,"type":33},{"date":211,"type":33},"2025-11-24",{"date":213,"type":22},"2031-06-30",{"name":215,"class":87},"Hoffmann-La Roche",{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":23,"phases":226,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":41},"100527945","action-observation-and-motor-imagery-therapy-in-parkinsons-disease-100527945","NCT06154356","Action Observation and Motor Imagery Therapy in Parkinson's Disease","Effect of Action Observation and Motor Imagery Therapy on Balance, Functional Status and Quality of Life in Parkinson's Disease, Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with a diagnosis of Parkinson's Disease\n* Hoehn and Yahr Stage 1-3\n\nExclusion Criteria:\n\n* Patients with cognitive dysfunction (those who cannot follow simple verbal instructions)\n* Patients with severe hearing problems\n* Patients with severe vision problems\n* Patients with additional musculoskeletal system pathology that will affect physical performance (such as amputation, severe joint mobility limitation, peripheral nerve damage)\n* Patients with uncontrolled hypertension and diabetes mellitus\n* Patients with a history of symptomatic lung disease (such as asthma, chronic obstructive pulmonary disease, emphysema)\n* Patients with a history of symptomatic cardiac disease (such as coronary artery disease, arrhythmia, heart failure)","65 Years",{"count":225,"type":22},54,[25],"In recent years, motor imagery (MI) and action observation (AO) therapy strategies have been used in rehabilitation programs to increase motor learning in Parkinson's disease (PD). Visuomotor training strategies such as AO and MI therapy rely on the activity of the mirror neuron system to facilitate motor re-learning. Mirror neurons are activated during the performance of goal-directed actions, also when observing the same action and visualizing the action in the mind.\n\nThe aim of this clinical trial is to test whether the application of AO and MI treatment in PD in addition to conventional rehabilitation programs has an additional effect on Balance, Functional Status and Quality of Life.",[28],"2026-08-03",{"date":231,"type":33},"2026-08-05",{"date":233,"type":33},"2023-12-14",{"date":235,"type":22},"2026-12",{"name":237,"class":40},"Karamanoğlu Mehmetbey University",{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":23,"phases":247,"briefSummary":248,"conditions":249,"keywords":250,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":41},"100626985","phase-2-neural-mechanisms-of-aerobic-exercise-benefits-in-pd-with-dbs-100626985","NCT07442747","Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS","Neural Mechanisms Underlying the Benefits of Aerobic Exercise in Advanced Parkinson's Disease","Inclusion Criteria:\n\n* Clinical diagnosis of Parkinson's disease\n* Previous placement of bilateral Medtronic Percept DBS as standard of care treatment for PD\n* Clinically optimized DBS parameters for one month prior to enrollment\n* Ability to ambulate with or without an assistive device for 5 continuous minutes\n* Willingness to withhold antiparkinsonian medication and DBS stimulation for outcomes assessments\n\nExclusion Criteria:\n\n* Neurocognitive impairment that compromises the ability to provide informed consent\n* Neurological disease other than Parkinson's disease (i.e. multiple sclerosis, stroke)\n* Recommendation for medical clearance using the American College of Sports Medicine (ACSM) Preparticipation Health Screen:\n\n  1. If the ACSM screen recommends medical clearance, the subject must obtain medical clearance by their health care provided prior to participation.\n  2. Those who choose not to obtain physician clearance will not be eligible for participation. Those who do not receive physician clearance for high intensity exercise will not be eligible.\n* A musculoskeletal issue (arthritis, osteoporosis, back problem) that would limit one's ability to engage in exercise\n* Current cardiac arrhythmia",{"count":246,"type":22},36,[182],"This study is focused on people with Parkinson's disease who already have deep brain stimulation devices. The goal is to understand how aerobic exercise, specifically forced vs voluntary cycling, affects movement, thinking, and brain activity in these individuals. Parkinson's disease is a progressive condition that impacts both movement and cognitive function. Previous research suggests aerobic exercise can improve PD symptoms, but the mechanisms underlying the improvement are not fully understood. This study aims to evaluate the neural (brain) mechanisms underlying exercise.",[28,55],[251,55,158,252,253,254,255,256,257,258,259,260,261],"Parkinson","Deep Brain Stimulation Surgery","DBS","Exercise","exercise training","Parkinson disease","Parkinson's","Parkinson's Disease with Deep Brain Stimulation","Percept","Cycling","Aerobic","2026-07-27",{"date":82,"type":33},{"date":265,"type":33},"2026-07-08",{"date":267,"type":22},"2029-12-31",{"name":269,"class":40},"The Cleveland Clinic",{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":12,"sex":18,"minAge":177,"maxAge":277,"enrollmentInfo":278,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":279,"conditions":280,"keywords":281,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":290,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":297},"100618333","a-us-study-that-observes-how-parkinsons-disease-changes-over-time-in-patients-who-still-have-movement-symptoms-despite-taking-parkinsons-medications-100618333","NCT07330258","A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications","A Natural History Study of Treated Parkinson's Disease Patients Experiencing Motor Complications","Inclusion Criteria for Patient:\n\n* Individual of any sex ≥45 to ≤75 years of age at informed consent (at least 30% ≤60 years of age).\n* Diagnosis of clinically established Parkinson's disease (PD) as defined by the Movement Disorder Society (MDS) Clinical Diagnostic Criteria for PD ≥4 and \\\u003C12 years from time of PD diagnosis at informed consent.\n* Modified H\\&Y stage II-III in the practically defined OFF-medication state (≥12 hours from last dose of antiparkinsonian medications).\n* Score of ≥30 on MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III in the OFF-medication state.\n* Presence of motor fluctuations with ≥1 hour of absolute time in the OFF state per day as assessed by clinician\u002Fpatient at screening.\n* Receiving stable antiparkinsonian medication regimen for ≥4 weeks prior to screening with a levodopa daily dose ≥300 mg or a dosing frequency of ≥3 times per day.\n* Responsiveness to levodopa as determined by change in the following measures from the practically defined OFF state to ON state after taking typical first-daily dose of PD-medications: i. any degree of improvement (≥0.5 point) in modified H\\&Y stage OR. ii. ≥30% improvement in MDS-UPDRS part III score.\n* Montreal Cognitive Assessment (MoCA) score of ≥24.\n* Agree to participate and provide signed informed consent.\n\nExclusion Criteria for Patient:\n\n* Known history or presence of conditions that may provide an alternative to a PD diagnosis including but not limited to: multiple system atrophy, progressive supranuclear palsy, striatonigral degeneration, corticobasal syndrome\u002Fdegeneration, vascular Parkinsonism, drug-induced Parkinsonism, essential tremor, diffuse Lewy body disease, Lewy body dementia, Huntington's disease, Wilson's disease, Fahr's disease, Alzheimer's disease, cerebrovascular disease, brain tumor, trauma, and infection.\n* Known history or presence of significant vascular and\u002For cardiovascular disease limited to: stroke, transient ischemic attacks, poorly controlled hypertension, poorly controlled diabetes, unstable angina pectoris, or unstable myocardial infarction.\n* Known history or presence of significant psychosis or impulse control disorder, or untreated or sub optimally treated depression.\n* Known history or presence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, syphilis, or tuberculosis.\n* Current or previously active malignant disease within the past 5 years, except definitively treated cutaneous squamous cell carcinoma, basal cell carcinoma, or in situ uterine cervical carcinoma.\n* Currently pregnant, nursing, lactating, breastfeeding, or plan to be during study duration.\n* Known history or current use of percutaneous levodopa\u002Fcarbidopa intestinal gel, subcutaneous levodopa, or apomorphine pump.\n* Prior history of brain surgery, including but not limited to: deep brain stimulation (DBS), pallidotomy, focused ultrasound thalamotomy, or other experimental neurosurgical procedure.\n* Known history or current participation in cell or gene therapy procedures.\n* Current participation in any interventional clinical trial.\n\nInclusion Criteria for Care Partner:\n\n* ≥18 years of age at informed consent.\n* Identified by the PD patient as their primary care partner.\n* Agree to participate and the ability to provide signed informed consent independently, without the need for a legal representative.\n\nExclusion Criteria for Care Partner:\n\n* Not applicable.","75 Years",{"count":50,"type":22},"This is an observational study in which data are collected and studied from Parkinson's disease patients who have movement symptoms despite taking standard Parkinson's medications. In observational studies, observations are made without any changes to the participant's healthcare or treatment plan. No investigational product will be administered in this study, as participants will be treated with the standard of care that medical experts currently consider most appropriate.\n\nParkinson's disease (PD) is a condition that affects the brain and causes problems with movement and other body functions. The symptoms of Parkinson's disease can worsen over time. People with Parkinson's disease may experience shaking (tremor), slow movements, stiff muscles, trouble walking, and problems with balance. They can also have other symptoms, such as difficulty thinking clearly, changes in mood, or difficulty sleeping. Parkinson's disease mostly affects older adults, but it can happen to younger people too. There is no cure, but treatments can help manage the symptoms and improve quality of life.\n\nWhile doctors and researchers know that Parkinson's disease affects people in different ways and can worsen over time, there are still many things they don't fully understand-especially for people who experience movement symptoms despite taking their usual Parkinson's medicines. Earlier studies did not follow these patients long enough or collect all the important information needed. This study is being done to fill those gaps.\n\nThe main purpose of this study is to better understand how Parkinson's disease changes over time in patients who experience movement symptoms while taking standard oral Parkinson's medications, what challenges patients and their care partners face, and how their treatments are working in real life. To do this, researchers will collect data on:\n\n* Sociodemographics (e.g. age, gender, race\u002Fethnicity, insurance provider).\n* Medical history and vital signs (e.g. comorbidities, family history of Parkinson's, height, weight, blood pressure).\n* Medications and treatments (e.g. Parkinson's and non-Parkinson's medications and other treatments, rehabilitation therapy sessions, use of mobility assistance devices).\n* Movement symptoms (e.g. tremor, slow movement, balance).\n* Non-movement symptoms (e.g. cognition, mood, sleep, activities of daily living).\n* Molecular data (e.g. genetics, α-synuclein).\n* Burden of care (e.g. economic cost).\n\nData will come from questionnaires or rating scales conducted by the doctor with the patient during study visits, diaries and logs completed by the patient, medical records, health insurance claims records, blood samples and skin biopsies, a digital device that records movement\u002Fnon-movement symptoms, and questionnaires completed by the care partner.\n\nData will be collected from December 2025 to December 2032. Each participant may be followed for up to 5 years.",[28],[282,158,283,284,285,286,287,288,289],"Natural history study","PD Motor (Hauser) Diary","MDS-UPDRS","Electronic health\u002Fmedical records","Administrative claims data","Biological samples","Digital health technology","Care partner",{"date":82,"type":33},{"date":292,"type":33},"2026-07-21",{"date":294,"type":22},"2033-06-01",{"name":296,"class":87},"Bayer",26,{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":12,"sex":18,"minAge":305,"maxAge":277,"enrollmentInfo":306,"targetDuration":4,"studyType":23,"phases":308,"briefSummary":309,"conditions":310,"keywords":311,"overallStatus":313,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":318,"leadSponsor":320,"locationsCount":41},"100649365","phase-1-phase-iii-clinical-trial-of-ux-da003-injection-for-the-treatment-of-patients-with-parkinsons-disease-100649365","NCT07733349","Phase I\u002FII Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease","Phase I\u002FII Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of UX-DA003 Injection in Patients With Parkinson's Disease","Inclusion Criteria:\n\n* Aged between 30 and 75 years, regardless of gender\n* Diagnosed with Parkinson's disease conforming to relevant clinical diagnostic standards with a medical history of 5-20 years\n* Having received standard anti-PD treatment and been given optimal anti-PD treatment under the guidance of the investigator, but the efficacy has significantly declined\n* Good response to levodopa medications, the levodopa challenge test (LCT) shows that the maximum improvement rate of the UPDRS-III score exceeds 30%\n* The modified H\\&Y staging (Off period) of ≥2.5 and ≤4, with total daily \"off\" time \\>2 hours\n* Stable dose of anti-Parkinson' disease drugs for at least 4 weeks prior to screening\n* Good physical condition or stable concomitant diseases\n\nExclusion Criteria:\n\n* The subjects with atypical Parkinson's syndrome or secondary Parkinson's syndrome\n* Severe systemic diseases or functional impairments\n* Evidence of active infection or chronic infection, which may pose a risk to the subject\n* Severe concomitant central nervous system diseases or severe cognitive and psychiatric disorders\n* Subjects with a history of brain injuries, cerebral vascular malformations, hydrocephalus, brain tumors, or other brain damages as shown by previous Head CT\u002FMRI scans, or subjects with abnormal brain imaging in the striatum or other brain regions that significantly increase surgical risks\n* Subjects who have participated in clinical trials for stem cell therapy or gene therapy for Parkinson's disease, or have participated in other interventional clinical trials within the last 3 months\n* Subjects with a history of severe allergies or hypersensitivity reactions, known hypersensitivity to the investigational drug or its ancillary materials, or intolerance to them\n* Pregnant or breastfeeding women","30 Years",{"count":307,"type":22},12,[76,182],"This clinical study is designed to explore the safety and tolerability of UX-DA003. It will also explore if UX-DA003 works to improve motor function in subjects with Parkinson's disease.",[28],[312,28],"allogeneic iPSC derived mDAPs","NOT_YET_RECRUITING","2026-07-24",{"date":316,"type":33},"2026-07-29",{"date":229,"type":22},{"date":319,"type":22},"2032-08-31",{"name":321,"class":87},"Shanghai UniXell Biotechnology Co., Ltd",{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":95,"sex":18,"minAge":329,"maxAge":330,"enrollmentInfo":331,"targetDuration":4,"studyType":23,"phases":333,"briefSummary":334,"conditions":335,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":41},"100423868","novel-dbs-stimulation-patterns-for-treatment-of-parkinsons-disease-100423868","NCT04799470","Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease","Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease - UNMC\u002FMedtronic Collaborative Acute Feasibility Pilot","Inclusion Criteria:\n\n* Patients with idiopathic Parkinson's Disease who were recommended for STN DBS using standard clinical inclusion and exclusion criteria (e.g., presence of coagulopathy, dementia, untreated depression, pre-existing implanted stimulation system, prior intracranial surgery, history of alcohol or drug abuse)\n* Patients have been previously implanted with bilateral STN DBS and the Medtronic Percept PC implantable neural stimulator.\n* Patients are optimized for clinical stimulation and medication for at least 3 months post-surgery for the implantation of their DBS system.\n* Consent to study participation\n* Presence of a robust beta peak (detectable using the Percept BrainSense Survey feature; ≥ 0.7 µV\u002FrtHz), intra-operatively (assessed via Lead Confirm technology from Alpha Omega)\n* Good response to stimulation (30% improvement on UPDRS III compared to baseline OFF), at least 3 months post-surgery.\n\nExclusion Criteria:\n\n* Not currently implanted with the Medtronic Percept INS\n* Not willing to participate in the study\n* Unstable stimulation with need for frequent reprogramming or further adjustment\n* Significant stimulation-induced side effects\n* Need for unusual programming parameters such as very high (\\> 200 Hz) or low (\\\u003C 100) frequencies (due to cycle limitations)\n* The patient has an implanted cardiac device\n* The patients Medtronic Percept TM PC indicates elective-replacement-indicated (ERI) at the start of the study","19 Years","80 Years",{"count":332,"type":22},10,[25],"This is an open-label, non-randomized, proof-of-concept comparison of clinical vs. research stimulation patterns in patients with Parkinson's disease (PD) being treated with Deep Brain Stimulation (DBS) through the Medtronic Percept PC DBS device. The investigators hypothesize that stimulation patterns designed to better target excessive synchrony in a patient-tailored manner may result in more efficient and effective therapy with fewer side effects. Medtronic 3rd-generation sensing implantable neural stimulator, Percept PC, is FDA-approved for treating PD. The Percept PC device features BrainSense, the first and only available sensing technology for deep brain stimulation. BrainSense technology allows the device to capture and record brain signals (local field potentials, or LFP) using the brain-implanted DBS lead, while simultaneously delivering therapeutic stimulation. Investigators plan to enroll and complete investigations in 15 study subjects total, who have been previously implanted with the Medtronic Percept PC for the treatment of PD, and who are optimized for clinical stimulation and anti-Parkinsons medication. Investigations will be performed in UNMC Movement Disorders Clinic, UNMC Neurosurgery Lab, and UNO Biomechanics Research Building, Gait Lab. Subjects will receive research stimulation patterns and the effect on PD motor symptoms will be assessed via Unified Parkinsons Disease Rating Scale (UPDRS)-part III and gait measures. Videotaping of patient UPDRS-III testing and gait will be obtained.",[28],"2026-07-20",{"date":338,"type":33},"2026-07-22",{"date":340,"type":33},"2021-05-10",{"date":342,"type":22},"2028-04",{"name":344,"class":40},"University of Nebraska",{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":353,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":355,"conditions":356,"keywords":357,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":307},"100622347","a-study-to-assess-change-in-disease-symptoms-in-adult-participants-with-advanced-parkinson-disease-using-subcutaneous-foslevodopafoscarbidopa-in-belgium-100622347","NCT07382440","A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa\u002FFoscarbidopa in Belgium","Observational Prospective Study to Evaluate Effectiveness of Subcutaneous Treatment With Foslevodopa\u002FFoscarbidopa in Real Life Setting for Advanced Parkinson's Disease Patients in Belgium.","ProParkB","Inclusion Criteria:\n\n* Participant diagnosed with Advanced Parkinson's Disease (PD), aged 18 years or older able to provide voluntary informed consent.\n* Participant evaluated for commercially available continuous subcutaneous Foslevodopa\u002FFoscarbidopa (LDp\u002FCDp) in the hospital at the clinician's discretion as part of his\u002Fher routine clinical care and the intention to administer subcutaneous LDp\u002FCDp made prior to and independent of recruitment into the study.\n\nExclusion Criteria:\n\n* Participant participating in an interventional research study (not including noninterventional studies) during the administration of LDp\u002FCDp.\n* Participant evaluated for commercially available continuous subcutaneous LD\u002FCDp outside of the hospital.",{"count":354,"type":22},120,"Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective Foslevodopa\u002FFoscarbidopa is in treating adult participants with advanced Parkinson Disease under routine clinical practice in Belgium.\n\nFoslevodopa\u002FFoscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 120 adult participants who are prescribed Foslevodopa\u002FFoscarbidopa by their doctors will be enrolled at 15 sites across Belgium.\n\nParticipants will receive Foslevodopa\u002FFoscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 18 months.\n\nThere is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.",[28],[358,359],"Parkinson's Disease: Advanced Parkinson's Disease","Foslevodopa\u002FFoscarbidopa",{"date":361,"type":33},"2026-07-10",{"date":363,"type":33},"2026-03-09",{"date":365,"type":22},"2028-09",{"name":367,"class":87},"AbbVie",{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":12,"sex":18,"minAge":201,"maxAge":375,"enrollmentInfo":376,"targetDuration":4,"studyType":23,"phases":378,"briefSummary":379,"conditions":380,"keywords":381,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":41},"100559318","non-invasive-vns-for-parkinsons-gait-100559318","NCT06562569","Non-invasive VNS for Parkinson's Gait","Stimulating the Vagus Nerve to Improve Gait in Veterans With Parkinson's Disease","Inclusion Criteria:\n\n* Parkinson's disease, as diagnosis by a VA neurologist\n* HY stages 2-3\n* Self-report Freezing of Gait\n* Able to ambulate for 2-min without an assistive device\n* Parkinson's disease medications are stable for 4-weeks and expected to be on stable medications for duration of the study\n\nExclusion Criteria:\n\nFor Group 1 and 2\n\n* Lack of decision-making capacity\n* Prescribed centrally acting anticholinergics (e.g., amitriptyline) or cholinesterase inhibitors\n* Musculoskeletal or additional neurological conditions that negatively impact gait and balance\n* Spine or LE surgery within the past year\n* Uncontrolled hypertension, hypotension, bradycardia, or tachycardia\n* History of baseline cardiac disease or atherosclerotic cardiovascular disease, including congestive heart failure, known severe coronary artery disease, severe carotid stenosis (e.g., bruits or history of TIA or stroke), or recent myocardial infarction (within 5 years).\n* Abnormal baseline electrocardiogram within last year\n* Previous vagotomy\n* Implanted metal cervical spine hardware, other metallic implants or implantable medical devices such as DBS\n* Active cancer\n* have previously had cancer in any areas where stimulation will occur\n* Documented abnormal cervical anatomy\n* History of brain tumor, aneurysm, bleed or head trauma\n* History of syncope or seizures (within the last 2 years)\n\nFor Group 3\n\n* Lack of decision-making capacity\n* Musculoskeletal or additional neurological conditions that negatively impact gait and balance\n* Spine or LE surgery within the past year","88 Years",{"count":377,"type":22},40,[25],"More than 110,000 US Veterans living with Parkinson's disease (PD) currently receive PD-related care and services from the VA. Fall prevention is a priority for Veterans living PD. Gait disturbances are a major cause for functional dependence and the largest risk factor for falls, institutionalization, and death in PD. This SPiRE addresses the need to advance nonpharmacological rehabilitative health care of Veterans and maximizing functional outcomes by developing a non-invasive, neuromodulatory transcutaneous cervical Vagal Nerve Stimulation as an at-home intervention to improve gait and balance. This pilot clinical trial will assist with future efforts and priorities of the VA to prolong independent living and quality of life by minimizing gait and balance dysfunction experienced by Veterans living with PD.",[28],[382,383,384,385,386],"vagal nerve stimulation","gait","neuromodulation","Freezing of gait","Veteran","2026-07-07",{"date":389,"type":33},"2026-07-09",{"date":391,"type":33},"2026-03-01",{"date":393,"type":22},"2027-04-01",{"name":395,"class":396},"VA Office of Research and Development","FED",{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":403,"eligibilityCriteria":404,"healthyVolunteers":95,"sex":18,"minAge":19,"maxAge":405,"enrollmentInfo":406,"targetDuration":4,"studyType":23,"phases":408,"briefSummary":409,"conditions":410,"keywords":411,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":429},"100184917","subthalamic-nucleus-akinesia-and-parkinsons-disease-100184917","NCT01682668","Subthalamic Nucleus, Akinesia and Parkinson's Disease","Role of the Subthalamic Nucleus in the Control of Movement: Physiopathology of Akinesia in Parkinson's Disease.","GB-MOV","Inclusion criteria for patients who will be operated\n\n1. Diagnosis of idiopathic Parkinson's disease (according to the criteria of the United Kingdom Parkinson's Disease Society Brain Bank)\n2. Age between 18 and 70;\n3. Motor complications in the form of fluctuations in motor state or dyskinesias induced by dopaminergic therapy, despite medical treatment optimum;\n4. Other medical conditions that are stable or do not interfere with the procedure proposed;\n5. Excellent responsiveness to levodopa (UPDRS motor score improvement greater than 50% in the acute levodopa test)\n6. Brain MRI without abnormality\n7. Normality of biological examinations\n8. Person who has voluntarily and informedly agreed to participate in the study (signature of a written consent)\n9. Patient with social health insurance\n\nCriteria for non-inclusion of Parkinsonian patients who will be operated\n\n1. Contraindication to examinations necessary for inclusion\n2. Evolutionary psychiatric pathology;\n3. Dementia(MMS\\\u003C24\u002F30);\n4. Patients with a medical condition that makes surgery dangerous neuro-surgical;\n5. Bleeding-promoting diseases and laboratory test abnormalities clotting;\n6. Existence of contraindications to MRI (cardiac or neural pacemaker, clips ferromagnetic surgeries, implants and metal objects, foreign bodies intraocular, pregnancy, claustrophobia).\n7. Taking drugs interfering with coagulation for 1 month before intervention.\n8. Persons under guardianship, curatorship or any other administrative or judicial measure deprivation of rights and liberty\n\nSelection criteria for non-operated patients\n\n1. Diagnosis of idiopathic Parkinson's disease (according to the criteria of the United Kingdom Parkinson's Disease Society Brain Bank);\n2. Age between 18 and 70;\n3. Other medical conditions that are stable or do not interfere with the proposed protocol;\n4. Presence of axial signs (gait and\u002For balance disorders) no improved by antiparkinsonian treatment\n5. Brain MRI without notable abnormality\n6. Normality of biological examinations\n7. Person who has voluntarily and informedly agreed to participate in the study (signature of a written consent)\n8. Patient with social health insurance\n\nCriteria for non-inclusion of non-operated patients\n\n1. Contraindication to examinations necessary for inclusion\n2. Progressive psychiatric pathology;\n3. Dementia (MMS\\\u003C24\u002F30);\n4. Existence of contraindications to MRI (cardiac or neural pacemaker, clips ferromagnetic surgeries, implants and metal objects, foreign bodies intraocular, pregnancy, claustrophobia).\n5. Persons under guardianship, curatorship or any other administrative or judicial measuredeprivation of rights and liberty\n\nInclusion criteria for group 3 patients (already operated)\n\n1. Diagnosis of idiopathic Parkinson's disease (according to the criteria of the United Kingdom Parkinson's Disease Society Brain Bank);\n2. Bilateral deep brain stimulation of the subthalamic nucleus for more than 1 year\n3. Age between 18 and 70;\n4. Person who has voluntarily and informedly agreed to participate in the study (signature of a written consent)\n5. Patient with social health insurance\n\nCriteria for non-inclusion of Parkinsonian patients (already operated)\n\n1. Contraindication to examinations necessary for inclusion\n2. Evolutionary psychiatric pathology;\n3. Dementia(MMS\\\u003C24\u002F30);\n4. Persons under guardianship, curatorship or any other administrative or judicial measure deprivation of rights and liberty\n\nInclusion criteria for healthy subjects\n\n1. Age between 18 and 70 years old\n2. Normal neurological examination\n3. Person who voluntarily and informedly agreed to participate in the study (signature of a written consent)\n4. Patient with social health insurance\n\nCriteria for non-inclusion of healthy subjects\n\n1. Persons under guardianship, curatorship or any other administrative or judicial measure of deprivation of rights and freedom\n2. Existence of neurological, orthopedic or psychiatric history\n3. Existence of contraindications to MRI (cardiac or neural pacemaker, ferromagnetic surgical clips, implants and metallic objects, foreign bodies intraocular, pregnancy, claustrophobia).","70 Years",{"count":407,"type":22},180,[25],"This program aims to understand the role of the subthalamic nucleus in the control of the movement in healthy humans and patients with Parkinson's disease, how the STN dysfunction contributes to akinesia and how the STN stimulation improves motor signs in PD patients .",[28],[412,413,414,415,416,417,418,419],"parkinson's disease","subthalamic nucleus","akinesia","gait initiation","neuronal activity","before STN stimulation","with STN stimulation","functional MRI","2026-07-06",{"date":387,"type":33},{"date":423,"type":33},"2013-02",{"date":425,"type":22},"2026-08",{"name":427,"class":428},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",2,{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":438,"enrollmentInfo":439,"targetDuration":4,"studyType":23,"phases":441,"briefSummary":442,"conditions":443,"keywords":448,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":41},"100586803","epidural-electrical-stimulation-to-support-hemodynamic-management-in-individuals-with-parkinsons-disease-100586803","NCT06920134","Epidural Electrical Stimulation to Support Hemodynamic Management in Individuals With Parkinson's Disease","Study on Preliminary Safety and Efficacy of the ARC-IM Therapy to Support Hemodynamic Management in People With Typical and Atypical Parkinson's Disease","PD-HemON","Inclusion Criteria:\n\n1. \\> 18 years old\n2. Typical or Atypical PD (including but not limited to Multiple System Atrophy, Pure Autonomic Failure, Progressive Supranuclear Palsy)\n3. Confirmed orthostatic hypotension with a test for verticalization\n4. Confirmed symptomatic orthostatic hypotension that makes daily activities particularly challenging as determined by the study clinicians\n5. Must provide and sign the Informed Consent before any study-related procedures\n6. Stable medical, physical, and psychological conditions given participant indication as considered by Investigators;\n7. Able to understand and interact with the study team in French or English\n8. Agrees to comply in good faith with all conditions of the study and to attend all scheduled appointments\n\nExclusion Criteria:\n\n1. Diseases and conditions that would increase the morbidity and mortality of the implantation surgery\n2. The inability to withhold antiplatelet\u002Fanticoagulation agents perioperatively\n3. History of myocardial infarction or cerebrovascular events within the past 6 months\n4. Unstable or significant medical condition that is likely to interfere with study procedures or likely to confound study endpoint evaluations as determined by the Investigator\n5. History or presence of major psychiatric disorders or major neurocognitive disorders as considered by the Investigators in accordance with the treating physician and treating neurologist\n6. Major changes in PD treatment planned until the end of the main study phase (such as DBS or dopamine-pump implantation)\n7. Inability to follow study procedures.\n8. Spinal anatomical abnormalities precluding surgery\n9. Presence of any indications requiring frequent MRIs.\n10. Current pregnancy or current breastfeeding\n11. Lack of effective or acceptable contraception for women of childbearing capacity\n12. Intention to become pregnant during the study\n13. Unable or unwilling to effectively use the study system or related devices by the participant or caretaker, as determined by the investigator\n14. Participation in another interventional study that might confound study endpoint evaluations\n15. Enrolment of the investigator, his\u002Fher family members, employees, and other dependent persons","90 Years",{"count":440,"type":22},5,[25],"The PD-HemON study aims to evaluate the safety and preliminary efficacy of ARC-IM Therapy (Epidural Electrical Stimulation) to support hemodynamic management in people with typical and atypical Parkinson's Disease, who suffer from orthostatic hypotension.",[444,28,445,446,447],"Hypotension Symptomatic","Orthostatic Hypotension, Dysautonomic","Multiple System Atrophy (MSA) With Orthostatic Hypotension","Multiple System Atrophy - Parkinsonian Subtype (MSA-P)",[449,450,451,452],"orthostatic hypotension","parkinson's disease","autonomic failure","hypotension","2026-07-02",{"date":387,"type":33},{"date":456,"type":33},"2025-07-03",{"date":458,"type":22},"2031-05-01",{"name":460,"class":40},"Ecole Polytechnique Fédérale de Lausanne",{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":465,"acronym":466,"eligibilityCriteria":467,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":468,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":470,"conditions":471,"keywords":472,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":41},"100582018","optimizing-deep-brain-stimulation-to-improve-visuomotor-function-in-parkinsons-disease-100582018","NCT06857851","Optimizing Deep Brain Stimulation to Improve Visuomotor Function in Parkinson's Disease","DBS strabismus","Inclusion Criteria:\n\n* Parkinson's disease with bilateral STN DBS\n* Availability of pre-operative MR images (with a T1-weighted, gradient-echo sequence) and ability to get post-operative MRI or CT scans\n* Hoehn and Yahr stage 2-4 when off medication, and a stable antiparkinsonian medication regimen and DBS parameter settings\n\nExclusion Criteria:\n\n* Previous surgical therapy for Parkinson's disease (other than DBS)\n* Dementia\n* Clinically significant untreated depression or anxiety\n* Clinical features suggestive of atypical parkinsonism",{"count":469,"type":22},80,"Inability to align and refocus the eyes on the objects at different depths, i.e., vergence impairment and strabismus, frequently affects the quality of life in patients with Parkinson's disease. The investigators study aims to understand the location-specific effects of subthalamic region deep brain stimulation on vergence and strabismus by integrating the patient-specific deep brain stimulation models and high-resolution eye-tracking measures. The knowledge gained will allow the investigators to find the most beneficial stimulation location and parameters for improving binocular coordination, strabismus, and vergence while preserving the ability to treat motor symptoms in Parkinson's disease.",[28],[158,157,413],{"date":387,"type":33},{"date":475,"type":33},"2026-02-01",{"date":477,"type":22},"2029-10-01",{"name":395,"class":396},{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":18,"minAge":201,"maxAge":330,"enrollmentInfo":486,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":487,"conditions":488,"keywords":489,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":41},"100637658","a-long-term-follow-up-study-of-the-severe-parkinsons-disease-patients-administered-the-ips101a-gene-therapy-product-100637658","NCT07629115","A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.","A Long-Term Follow-up Study to Evaluate the Safety and Efficacy of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product in the IPS101A-10 Phase I Clinical Trial","Inclusion Criteria\n\n* Subjects who were enrolled in the IPS101A-10 clinical trial and received IPS101A.\n* Subjects and\u002For their legally acceptable representatives who voluntarily provided written informed consent to participate in this long-term follow-up study after being fully informed of the study, and who agreed to comply with all study-related requirements.\n\nExclusion Criteria\n\n* Subjects who decline to provide consent for participation in the long-term follow-up study, or for whom follow-up assessments are not feasible due to death or other reasons.\n* Subjects who, in the judgment of the investigator, are considered unsuitable for participation in the study due to unwillingness or inability to comply with scheduled study visits or other study-related requirements.",{"count":74,"type":22},"The purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.",[135,28],[490,491,492],"Adeno-associated Virus","Gene therapy","AAV","2026-06-29",{"date":495,"type":33},"2026-07-01",{"date":497,"type":33},"2026-05-29",{"date":499,"type":22},"2031-10-30",{"name":501,"class":87},"Innopeutics Corporation",{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":12,"sex":18,"minAge":305,"maxAge":178,"enrollmentInfo":509,"targetDuration":4,"studyType":23,"phases":510,"briefSummary":511,"conditions":512,"keywords":513,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":515,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":41},"100508545","phase-1-safety-and-efficacy-of-autologous-insc-dap-in-the-treatment-of-parkinsons-disease-100508545","NCT05901818","Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease","Safety and Efficacy of Autologous Induced Neural Stem Cell-derived Dopaminergic Precursor Cells in the Treatment of Parkinson's Disease","Inclusion Criteria:\n\nAges between 30 and 85 years, males or females; Diagnosed to be Parkinson's disease patients according to MDS Parkinson's disease diagnostic criteria; Disease history over 3 years; Hoehn and Yahr Stage less than or equal to 4 during the medication \"on\" time; Responsive to levodopa treatment (Maximum rate of improvement in MDS-UPDRS, part 3, is over 30%).\n\nExclusion Criteria:\n\nAtypical Parkinsonian syndrome or secondary Parkinsonian syndrome; Accompanied with other central nervous system diseases; With other severe systemic diseases or dysfunction; With severe psychiatric disorders; Subjects are using hormone or cytotoxic drugs and cannot stop taking the drug during the trial; With cognitive disorders (MMSE\\\u003C24); With severe dyskinesia (MDS-UPDRS part 4, score in 4.1\u002F4.2 ≥ 2); Subjects have undergone previous brain surgery; Subjects are long-term user of anticoagulant; Subjects have intracranial lesions which may affect the surgery or follow-up studies as assessed by imaging; Subjects are unable to undergo MRI or AV133 PET examination; Pregnancy or in preparation for pregnancy; Not suitable to participate in this clinical trial as assessed by the study investigators\u002Fphysicians.",{"count":74,"type":22},[76],"This is a phase I, interventional, single arm, open-label, clinical study to evaluate the safety and efficacy of the striatal transplantation of autologous induced neural stem cell-derived DA precursor cells in Parkinson's Disease patients.",[28],[514],"Autologous; iNSC; DA precursor cells; Parkinson's Disease; Cell therapy; Stereotaxic injection",{"date":495,"type":33},{"date":517,"type":33},"2021-04-01",{"date":519,"type":22},"2028-12-31",{"name":521,"class":40},"Xuanwu Hospital, Beijing",{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":12,"sex":18,"minAge":305,"maxAge":330,"enrollmentInfo":529,"targetDuration":4,"studyType":23,"phases":531,"briefSummary":532,"conditions":533,"keywords":536,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":41},"100636786","individualized-transcranial-magnetic-stimulation-in-parkinsonian-disorders-100636786","NCT07570212","Individualized Transcranial Magnetic Stimulation in Parkinsonian Disorders","Exploration of the Efficacy of Individualized Transcranial Magnetic Stimulation in the Treatment of Parkinsonian Disorders","Inclusion Criteria:\n\n1. Diagnostic Criteria Clinically established or clinically probable Parkinson's Disease (PD) according to the 2015 International Parkinson and Movement Disorder Society (MDS) diagnostic criteria; Clinically established or clinically probable Multiple System Atrophy (MSA) according to the 2022 MDS diagnostic criteria; Clinically probable or clinically possible Progressive Supranuclear Palsy (PSP) according to the 2017 MDS diagnostic criteria.\n2. Demographics Aged 30 to 80 years, inclusive; no gender restrictions.\n3. Disease Severity and Staging PD: Modified Hoehn and Yahr (H-Y) stage 2-4; MSA: Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV stage 1-4; PSP: Modified Rankin Scale (mRS) grade 2-4.\n4. Informed Consent and Compliance Ability to understand and comply with the study requirements and provide written informed consent.\n\nExclusion Criteria:\n\n1. Contraindications to TMS Presence of intracranial metallic implants or other foreign bodies, including but not limited to cochlear implants, cardiac pacemakers, or internal metallic\u002Fmagnetic fragments.\n2. Contraindications to EEG and MRI EEG: Known allergy to conductive paste or other EEG-related contraindications. MRI: History of claustrophobia, presence of MRI-incompatible implants, or extensive tattoos.\n3. Concurrent Physical Therapies Currently receiving Transcranial Magnetic Stimulation (TMS) or other therapeutic physical modalities, such as Transcranial Direct Current Stimulation (tDCS).\n4. Unstable Medical Conditions Presence of unstable systemic diseases requiring urgent pharmacological or surgical intervention.\n5. Neurological and Psychiatric History Personal or family history of epilepsy; History of moderate-to-severe psychiatric or psychological disorders; Chronic insomnia or regular use of sedative-hypnotics; Current use of medications that significantly alter central nervous system excitability.",{"count":530,"type":22},50,[25],"This clinical trial aims to evaluate whether individualized targeted repetitive transcranial magnetic stimulation (rTMS) can improve motor and non-motor symptoms in patients with parkinsonian disorders. The main question it aims to answer is:\n\n* Does individualized targeted rTMS alleviate symptoms of parkinsonian disorders?\n* Which clinical manifestations of parkinsonian syndromes are responsive to individualized targeted rTMS, and to what degree?\n\nProcedures:\n\n* Preparation (Screening) Participants will undergo clinical assessments, MRI, and EEG before the treatment.\n* Treatment (2 Weeks) Participants will receive a 10-day TMS treatment (once daily, Monday-Friday). Each treatment day takes approximately 3-4 hours. Participants need to keep stable medications and rehabilitation routines during this time.\n* Follow-up (10 Weeks) Participants will undergo follow-up assessments at the end of treatment and 10 weeks after treatment. Assessments include clinical scales, MRI, and EEG.",[28,534,535],"Multiple System Atrophy","Progressive Supranuclear Palsy",[537,538,539],"parkinsonian disorders","transcranial magnetic stimulation","somato-cognitive action network","2026-06-24",{"date":493,"type":33},{"date":543,"type":33},"2025-12-22",{"date":545,"type":22},"2027-12-22",{"name":547,"class":40},"Peking University First Hospital",{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":23,"phases":556,"briefSummary":557,"conditions":558,"keywords":559,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":440},"100609622","adaptive-dbs-algorithm-for-personalized-therapy-in-parkinsons-disease-adapt-pd-china-study-100609622","NCT07216976","Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study","Inclusion Criteria:\n\n1. Subjects must meet all general inclusion\u002Fexclusion criteria (as assessed at the Enrollment Visit)\n2. Subjects must meet the LFP screening inclusion criterion (as assessed at the LFP Screening Visit)\n\nGeneral (Assessed at Enrollment Visit):\n\n1. Subject has idiopathic Parkinson's disease\n2. Subject is implanted (\\>3 months prior to enrollment for new INS implants or \\>1 month from INS replacement) with a Percept PC (Model B35200) or Percept RC (Model B35300) and Medtronic DBS leads (Model 3387, 3389, B33005 or B33015) and extensions (Model 37086 or B34000) bilaterally in the same target (physician confirmed), STN or GPi\n3. In the opinion of the investigator, the subject responds to DBS Therapy.\n4. Based on the opinion of the investigator, the subject's cDBS parameters and PD medications are stable (no changes within the last 4 weeks) and expected to remain stable from enrollment through the end of the aDBS Evaluation Phase\n5. Subject is configured to monopolar or dual monopolar stimulation using contacts 1 and\u002For 2 (9 and\u002For 10) on at least one side\n6. Subject is willing and able to attend all study-required visits and complete the study procedures (e.g. 1-month recall questionnaires, MDS-UPDRS III, Off stim\u002FOff med visit)\n7. Subject (or legally authorized representative) has the ability to understand and provide written informed consent for participation in the study prior to the study-related procedures being conducted\n8. Subject is a male or non-pregnant female. If female of child-bearing potential, and if sexually active, must be using, or agree to use, a medically-acceptable method of birth control as confirmed by the investigator\n\nLFP Screening Inclusion Criteria (Conducted during LFP Screening Visit):\n\n1\\. Subject has Alpha - Beta band (8-30 Hz) amplitude ≥ 1.2 μVp detected on either left and\u002For right DBS leads on sensing channels 0-2, 0-3, 1-3, 8-10, 8-11, or 9-11.\n\nExclusion Criteria:\n\nGeneral (Assessed at the Enrollment Visit):\n\n1. Subject and\u002For caregiver is unable to utilize the patient programmer\n2. Subject has more than one lead in each hemisphere of the brain\n3. Subject has cortical leads or additional unapproved hardware implanted in the brain\n4. Subject has more than one INS\n5. At enrollment, the subject's INS has a predicted battery life of \\\u003C1 year\n6. Subject has Beck Depression Inventory II (BDI-II)\\>25\n7. Subject requires diathermy, transcranial magnetic stimulation (TMS), or electroconvulsive therapy (ECT)\n8. Subject has a metallic implant in the head, (e.g., aneurysm clip, cochlear implant)\n9. Subject has, or plans to obtain, an implanted electrical stimulation medical device anywhere in the body (e.g., cardiac pacemaker, defibrillator, spinal cord stimulator)\n10. Subject has, or plans to obtain, an implanted medication pump for the treatment of Parkinson's disease (e.g., DUOPATM infusion pump) and\u002For portable infusion pump\n11. Based on the opinion of the investigator, the subject has an abnormal neurological examination that would preclude them from study participation\n12. Subject is breast feeding\n13. Subject is under the age of 18 years\n14. Subject is currently enrolled in or plans to enroll in any concurrent drug and\u002For device study that may confound the results of this study as determined by the Medtronic study team\n15. Subjects with signal artifact on all 6 aDBS sense pathways (3 each on both DBS leads) which preclude the clinician from setting thresholds",{"count":555,"type":22},62,[25],"The purpose of the study is to evaluate the effectiveness of the Medtronic Adaptive DBS therapy (aDBS) for Parkinson's Disease in China with the Percept family of Implantable Neurostimulators (Percept PC and Percept RC).",[28],[55],{"date":561,"type":33},"2026-06-26",{"date":563,"type":33},"2025-11-19",{"date":565,"type":22},"2028-01",{"name":567,"class":87},"MedtronicNeuro",{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":572,"acronym":4,"eligibilityCriteria":573,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":574,"targetDuration":4,"studyType":23,"phases":576,"briefSummary":577,"conditions":578,"keywords":581,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":584,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":41},"100567700","effects-of-osteopathic-manipulative-treatment-protocol-on-sleep-quality-in-parkinsons-disease-subjects-100567700","NCT06671600","Effects of Osteopathic Manipulative Treatment Protocol on Sleep Quality in Parkinson's Disease Subjects","Inclusion Criteria:\n\n* Must have a diagnosis of Parkinson's disease as per a neurologist\n* Severity of 0-3 on the Hoehn and Yahr (H-Y) Scale\n* Able to receive OMM\n* Able to be in a supine and prone position.\n* Able to wear a Fitbit watch and an oxygen saturation ring for the duration of the study (including when sleeping).\n* Have sleep disturbance complaints.\n\nExclusion Criteria:\n\n* Patients on medications that affect sleep\n* Have a pre-existing sleep disorder diagnosis\n* Those who have a concurrent neurological diagnosis that would confound sleep patterns (ie. narcolepsy)\n* Contraindications to the OMM techniques used in this protocol\n* Severity of 4 and 5 on the Hoehn and Yahr Scale",{"count":575,"type":22},32,[25],"Parkinsonism, mainly caused by Parkinsons disease (PD), includes symptoms like tremors, stiffness, slow movements, and balance problems. These symptoms can make it hard for people to sleep well, which leads to a lower quality of life and can increase the risk of other health issues and cognitive decline.\n\nOsteopathic manipulative treatment (OMT) is a hands-on approach that may help improve sleep without the side effects of traditional treatments. While OMT has shown promise in enhancing sleep, no studies have specifically looked at its effects on sleep in Parkinson's disease patients.\n\nThis study aims to see if OMT can help improve sleep quality, cognitive function, and daily activities for people with PD. The investigators will focus on treating specific areas of the body, using techniques that have helped improve sleep in the past.\n\nParticipants will be divided into two groups: one will receive OMT, while the other will get a light touch treatment as a control. Sleep surveys and data from Fitbit devices will be used to compare the effects of the two treatments. Additionally, cognitive function will be assessed using a specific task called the Stroop task.\n\nThis research could show that OMT can be a valuable addition to treatments for improving sleep quality in people with Parkinsons disease.",[579,580],"Parkinsons Disease","Sleep",[582,580,579,583],"OMM","Osteopathy",{"date":493,"type":33},{"date":586,"type":33},"2025-08-01",{"date":588,"type":22},"2027-12-31",{"name":590,"class":40},"New York Institute of Technology",{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":595,"acronym":4,"eligibilityCriteria":596,"healthyVolunteers":95,"sex":18,"minAge":597,"maxAge":48,"enrollmentInfo":598,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":600,"conditions":601,"keywords":603,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":41},"100471009","natural-history-protocol-for-movement-disorders-100471009","NCT05413291","Natural History Protocol for Movement Disorders","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged 2 and above\n* Either one of these:\n\n  * Have or suspected to have a diagnosis of a movement disorder.\n  * Family member of someone who has or is suspected of having a diagnosis of a movement disorder.\n* Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets the following criteria will be excluded from participation in this study:\n\n-Being \\\u003C 2 years old.","2 Years",{"count":599,"type":22},4000,"Background:\n\nA movement disorder is a condition that causes a person s body to move in ways that are not normal. There are different types. Some disorders cause movements people can t control, such as tics or shaking. Some cause reduced or slow movements. Movement disorders can cause disability in people. Sometimes members of the same family will have the same disorder. Researchers want to learn more about how people develop these disorders. This research could lead to better treatments.\n\nObjective:\n\nThis natural history study will collect data on people with different types of movement disorders. It will also collect data on their family members. The data will support further research.\n\nEligibility:\n\nChildren and adults aged 2 years and older who have a movement disorder. Family members of people with movement disorders are also needed.\n\nDesign:\n\nParticipants will undergo screening. They will have a physical exam. Researchers will look at their existing medical images. Any photographs or videos of their movements will also be reviewed.\n\nMost participants will come to the NIH clinic for only 1 visit. They will answer questions about their condition. They will have normal tests used to diagnose their condition. They may have blood tests and different types of imaging scans. They may have tests to see how well their nerves function. The tests used will depend on the type of disorder they have.\n\nFamily members will have some of the same tests as people with disorders.\n\nParticipants will not receive any new treatments.\n\nSome participants may be asked to return for a follow-up visit.\n\nUp to 4000 people may participate.",[134,602,28],"Tremor",[134,602,28,604],"Natural History",{"date":606,"type":33},"2026-06-25",{"date":608,"type":33},"2022-10-17",{"date":610,"type":22},"2030-12-31",{"name":65,"class":66},{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":4,"eligibilityCriteria":618,"healthyVolunteers":12,"sex":18,"minAge":619,"maxAge":330,"enrollmentInfo":620,"targetDuration":4,"studyType":23,"phases":622,"briefSummary":623,"conditions":624,"keywords":4,"overallStatus":313,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":633,"leadSponsor":635,"locationsCount":4},"100641633","hf-rtms-primed-balance-training-on-corticomotor-excitability-balance-and-gait-in-parkinsons-100641633","NCT07653256","HF-rTMS Primed Balance Training on Corticomotor Excitability, Balance, and Gait in Parkinson's","Effects of High-frequency Repetitive Transcranial Magnetic Stimulation-primed Balance Training on Corticomotor Excitability, Balance, and Gait Performance in Parkinson's Disease","Inclusion Criteria:\n\n* Diagnosed with idiopathic PD\n* Aged between 40-80 years\n* Stable on antiparkinsonian medication ( \\> 3 months)\n* H\\&Y I-III\n* Able to walk continuously for at least 10 minutes\n* The ability to follow commands and instructions\n\nExclusion Criteria:\n\n* Neurological diseases other than PD\n* Severe musculoskeletal, cardiopulmonary disorders\n* MMSE \\\u003C 24\n* Contraindications for TMS\n* Have undergone or are scheduled to undergo neurological surgery during the study participation period","40 Years",{"count":621,"type":22},20,[25],"This study aims to investigate the effects of repeated transcranial magnetic stimulation combined with modified otago exercise program balance training intervention on motor cortex excitability, balance, and gait performance in patients with Parkinson's disease.",[28,625,626,627,628],"Corticomotor Excitability","Balance Control","Gait Performance","Motor Symptoms","2026-06-11",{"date":631,"type":33},"2026-06-17",{"date":495,"type":22},{"date":634,"type":22},"2028-04-01",{"name":636,"class":40},"Chung Shan Medical University"]